Wedbush Predicts Weaker Earnings for ORIC Pharmaceuticals

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) – Analysts at Wedbush dropped their Q1 2025 earnings per share (EPS) estimates for shares of ORIC Pharmaceuticals in a research note issued to investors on Tuesday, February 18th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of ($0.52) per share for the quarter, down from their prior forecast of ($0.47). Wedbush has a “Outperform” rating and a $20.00 price target on the stock. The consensus estimate for ORIC Pharmaceuticals’ current full-year earnings is ($2.16) per share. Wedbush also issued estimates for ORIC Pharmaceuticals’ Q2 2025 earnings at ($0.54) EPS, Q3 2025 earnings at ($0.55) EPS, Q4 2025 earnings at ($0.57) EPS, FY2025 earnings at ($2.17) EPS, FY2026 earnings at ($2.00) EPS and FY2027 earnings at ($2.14) EPS.

ORIC Pharmaceuticals (NASDAQ:ORIC) last announced its quarterly earnings results on Tuesday, February 18th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.01.

A number of other equities research analysts have also issued reports on the company. JPMorgan Chase & Co. boosted their target price on ORIC Pharmaceuticals from $19.00 to $21.00 and gave the stock an “overweight” rating in a research report on Thursday, February 6th. Guggenheim reaffirmed a “buy” rating on shares of ORIC Pharmaceuticals in a research report on Monday, February 10th. Wells Fargo & Company initiated coverage on ORIC Pharmaceuticals in a research report on Thursday, October 31st. They set an “overweight” rating and a $20.00 target price on the stock. HC Wainwright reissued a “buy” rating and set a $21.00 price target on shares of ORIC Pharmaceuticals in a research report on Friday. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of ORIC Pharmaceuticals in a research report on Tuesday, January 14th. Nine research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $18.71.

ORIC Pharmaceuticals Stock Performance

ORIC opened at $7.68 on Friday. ORIC Pharmaceuticals has a one year low of $6.33 and a one year high of $16.65. The stock’s fifty day moving average is $9.27 and its 200-day moving average is $9.49. The company has a market capitalization of $545.49 million, a PE ratio of -4.22 and a beta of 1.21.

Hedge Funds Weigh In On ORIC Pharmaceuticals

A number of hedge funds have recently modified their holdings of ORIC. Boxer Capital Management LLC bought a new stake in ORIC Pharmaceuticals during the 4th quarter worth approximately $13,982,000. Schonfeld Strategic Advisors LLC bought a new position in shares of ORIC Pharmaceuticals in the 4th quarter worth $5,845,000. Balyasny Asset Management L.P. boosted its position in shares of ORIC Pharmaceuticals by 37.5% in the 4th quarter. Balyasny Asset Management L.P. now owns 1,555,260 shares of the company’s stock worth $12,551,000 after purchasing an additional 424,194 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of ORIC Pharmaceuticals by 152.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 410,229 shares of the company’s stock worth $4,205,000 after purchasing an additional 247,863 shares during the last quarter. Finally, Diadema Partners LP acquired a new stake in ORIC Pharmaceuticals during the 4th quarter worth $1,729,000. 95.05% of the stock is owned by institutional investors and hedge funds.

Insider Activity at ORIC Pharmaceuticals

In other ORIC Pharmaceuticals news, CFO Dominic Piscitelli sold 8,851 shares of the company’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $8.28, for a total value of $73,286.28. Following the completion of the transaction, the chief financial officer now owns 106,764 shares of the company’s stock, valued at $884,005.92. This represents a 7.66 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Jacob Chacko sold 24,660 shares of the company’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $8.28, for a total value of $204,184.80. Following the completion of the transaction, the chief executive officer now directly owns 778,648 shares of the company’s stock, valued at approximately $6,447,205.44. This trade represents a 3.07 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 42,361 shares of company stock worth $350,749 in the last 90 days. 5.55% of the stock is owned by company insiders.

ORIC Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.